Topical metal chelation therapy ameliorates oxidation-induced toxicity in diabetic cataract

Journal of Toxicology and Environmental Health - Part A: Current Issues

Volumn 74, Issue 6, 2011, Pages 380-391

  Zhang, Min ^a   Shoeb, Mohammad ^a   Liu, Ping ^a   Xiao, Tianlin ^a   Hogan, Dale ^a   Wong, Ira G ^b   Campbell, Gerald A ^a   Ansari, Naseem H ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNONENAL; DIMETHYL SULFONE; EDETIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATARACT; CATARACTOGENESIS; CELL PROLIFERATION; CELL SWELLING; CHELATION THERAPY; CONTROLLED STUDY; EPITHELIUM CELL; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

ADMINISTRATION, TOPICAL; ALDEHYDES; ANIMALS; CATARACT; CELL PROLIFERATION; CHELATING AGENTS; CHELATION THERAPY; DIABETES COMPLICATIONS; DIMETHYL SULFOXIDE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EDETIC ACID; EPITHELIAL CELLS; LENS, CRYSTALLINE; MALE; METALS; OXIDATION-REDUCTION; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; SULFONES;

RATTUS;

EID: 79251621782     PISSN: 15287394     EISSN: 10872620     Source Type: Journal    
DOI: 10.1080/15287394.2011.538835     Document Type: Article

References (41)

1. Ansari, N. H., Wang, L., and Srivastava, S. K. 1996. Role of lipid aldehydes in cataractoge-nesis: 4-Hydroxynonenal-induced cataract. Biochem. Mol. Med. 58:25-30.
2. Buss, J. L., Greene, B. T., Turner, J., Torti, F. M., and Torti, S. V. 2004. Iron chelators in can-cer chemotherapy. Curr. Top. Med. Chem. 4:1623-1635.
3. Chen, J. J., and Yu, B. P. 1994. Alterations in mitochondrial membrane fluidity by lipid peroxidation products. Free Radical Biol. Med. 17:411-418.
4. Chiu, C. J., Milton, R. C., Klein, R., Gensler, G., and Taylor, A. 2007. Dietary carbohydrate and the progression of age-related macular degeneration: A prospective study from the Age-Related Eye Disease Study. Am. J. Clin. Nutr. 86:1210-1218.
5. Choudhary, S., Zhang, W., Zhou, F., Campbell, G. A., Chan, L. L., Thompson, E. B., and Ansari, N. H. 2002. Cellular lipid perox-idation end-products induce apoptosis in human lens epithelial cells. Free Radical Biol. Med. 32:360-369.
6. Christen, W. G., Jr. 1994. Antioxidants and eye disease. Am. J. Med. 97:14S-17S; discussion 22S-28S.
7. Congdon, N., O'Colmain, B., Klaver, C. C., Klein, R., Munoz, B., Friedman, D. S., Kempen, J., Taylor, H. R., and Mitchell, P. 2004. Causes and prevalence of visual impairment among adults in the United States. Arch. Ophthalmol. 122:477-485.
8. Cooper, G. J., Chan, Y. K., Dissanayake, A. M., Leahy, F. E., Keogh, G. F., Frampton, C. M. Gamble, G. D., Brunton, D. H., Baker, J. R., and Poppitt, S. D. 2005. Demonstration of a hyperglycemia-driven pathogenic abnor-mality of copper homeostasis in diabetes and its reversibility by selective chelation: Quantitative comparisons between the biol-ogy of copper and eight other nutritionally essential elements in normal and diabetic individuals. Diabetes 54:1468-1476.
9. Esterbauer, H. 1993. Cytotoxicity and geno-toxicity of lipid-oxidation products. Am. J. Clin. Nutr. 57:779S-785S; discussion 785S-786S.
10. Esterbauer, H., Schaur, R. J., and Zollner, H. 1991. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radical Biol. Med. 11:81-128.
11. Garland D. 1990. Role of site-specific, metal-catalyzed oxidation in lens aging and cataract: a hypothesis. Exp. Eye Res. 50 677-682.
12. Garner, B., Roberg, K., Qian, M., Eaton, J. W., and Truscott, R. J. W. 2000. Distribution of ferritin and redox-active transition metals in normal and cataractous human lenses. Exp. Eye Res. 71:599-607.
13. He, X., Hahn, P., Iacovelli, J., Wong, R., King, C., Bhisitkul, R., Massaro-Giordano, M., and Dunaief, J. L. 2007. Iron homeostasis and toxicity in retinal degeneration. Prog. Retina Eye Res. 26:649-673.
14. Kruszewski, M. 2004. The role of labile iron pool in cardiovascular diseases. Acta Biochim. Pol. 51:471-480.
15. Kupfer, C. 1985. Bowman lecture. The con-quest of cataract: a global challenge. Trans Ophthalmol. Soc. UK 104(Pt 1):1-10.
16. Kyselova, Z., Stefek, M., and Bauer, V. 2004. Pharmacological prevention of dia-betic cataract. J. Diabetes Complications 18:129-140.
17. Lassen, N., Bateman, J. B., Estey, T., Kuszak, J. R., Nees, D. W., Piatigorsky, J., Duester, G., Day, B. J., Huang, J., Hines, L. M., and Vasiliou, V. 2007. Multiple and addi-tive functions of ALDH3A1 and ALDH1A1: Cataract phenotype and ocular oxida-tive damage in Aldh3a1 (-/-)/Aldh1a1(-/-) knock-out mice. J. Biol. Chem. 282:25668-25676.
18. Liu, G., Men, P., Harris, P. L., Rolston, R. K., Perry, G., and Smith, M. A. 2006. Nanoparticle iron chelators: A new ther-apeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. Neurosci. Lett. 406:189-193.
19. Mansford, K. R. L., and Opie, L. 1968. Comparison of metabolic abnormalities in diabetes mellitus induced by streptozotocin or by alloxan. Lancet 291:670-671.
20. Michiels, C., Raes, M., Toussaint, O., and Remacle, J. 1994. Importance of SE-glutathione peroxidase, catalase, and CU/ZN-SOD for cell survival against oxidative stress. Free Radical Biol. Med.17:235-248.
21. Minassian, D. C., Reidy, A., Desai, P., Farrow, S., Vafidis, G., and Minassian, A. 2000. The deficit in cataract surgery in England and Wales and the escalating problem of visual impairment: Epidemiological modelling of the population dynamics of cataract. Br. J. Ophthalmol. 84:4-8.
22. Omoto, A., Kawahito, Y., Prudovsky, I., Tubouchi, Y., Kimura, M., Ishino, H., Wada, M., Yoshida, M., Kohno, M., Yoshimura, R., Yoshikawa, T., and Sano, H. 2005. Copper chelation with tetrathiomolybdate suppresses adjuvant-induced arthritis and inflammation-associated cachexia in rats. Arthritis Res.Ther. 7:R1174-R1182.
23. Ou, P., Nourooz-Zadeh, J., Tritschler, H. J., and Wolff, S. 1996. Activation of aldose reduc-tase in rat lens and metal-ion chelation by aldose reductase inhibitors and lipoic acid. Free Radical Res. 25:337-346.
24. Pryor, W. A., and Porter, N. A. 1990. Suggested mechanisms forthe production of 4-hydroxy-2-nonenal from the autoxidation of polyunsaturated fatty acids. Free Radical Biol. Med. 8:541-543.
25. Saaddine, J., Benjamin, S., Pan, L., Venkat Narayan, K. M., Tierney, E., Kanjilal, S., and Geiss, L. 2004. Prevalence of visual impair-ment and selected eye diseases among per-sons aged >50 years with and without diabetes\United States, 2002. Morbid. Mortal. Weekly Rep. 53:1069-1071.
26. Saxena, P., Saxena, A. K., Cui, X.-L., Obrenovich, M., Gudipaty, K., and Monnier, V M. 2000. Transition metal-catalyzed oxi-dation of ascorbate in human cataract extracts: Possible role of advanced glycation end products. Invest. Ophthalmol. Visual Sci. 41:1473-1481.
27. Sies, H. 1993. Strategies of antioxidant defense. Eur. J. Biochem. 215:213-219.
28. Sies, H. 1997. Oxidative stress: Oxidants and antioxidants. Exp. Physiol. 82:291-295.
29. Spector, A. 2000. Review: Oxidative stress and disease. J. Ocul. Pharmacol. Ther. 16: 193-201.
30. Srivastava, S. K., and Ansari, N. H. 1988. Prevention of sugar-induced cataractogen-esis in rats by butylated hydroxytoluene. Diabetes 37:1505-1508.
31. Srivastava, S. K., Ansari, N. H., and Bhatnagar, A. 1990. Sugar induced cataractogenesis: A paradigm of oxidative tissue pathology? Lens Eye Toxic. Res. 7:161-171.
32. Stohs, S. J., and Bagchi, D. 1995. Oxidative mechanisms in the toxicity of metal ions. Free Radical Biol. Med. 18:321-336.
33. Subramaniam, R., Roediger, F., Jordan, B., Mattson, M. P., Keller, J. N., Waeg, G., and Butterfield, D. A. 1997. The lipid peroxi-dation product, 4-hydroxy-2-trans-nonenal, alters the conformation of cortical synapto-somal membrane proteins. J. Neurochem. 69:1161-1169.
34. Truscott, R. J. W. 2005. Age-related nuclear cataract-oxidation is the key. Exp. Eye Res. 80:709-725.
35. van Meeteren, M. E., Teunissen, C. E., Dijkstra, C. D., and van Tol, E. A. 2005. Antioxidants and polyunsaturated fatty acids in multiple sclerosis. Eur. J. Clin. Nutr. 59: 1347-1361.
36. Winterbourn, C. C. 1995. Toxicity of iron and hydrogen peroxide: the Fenton reaction. Toxicol. Lett. 82-83:969-974.
37. Woollard, A. C., Wolff, S. P., and Bascal, Z. A. 1990. Antioxidant characteristics of some potential anticataractagents. Studies of aspirin, paracetamol, and bendazac provide support for an oxidative component of cataract. Free Radical Biol. Med. 9:299-305.
38. Xiao, T., Choudhary, S., Vergara, L. A., Van Kuijk, F. J. G. M., and Ansari, N. H. 2004. Oxidative stress induced formation of 4-hydroxynonenal- protein adducts in lens epithelium: Implication in oxidative catarac-togenesis. J. Tissue Res. 4:181-188.
39. Zecca, L., Youdim, M. B., Riederer, P., Connor, J. R., and Crichton, R. R. 2004. Iron, brain ageing and neurodegenera-tive disorders. Nat Rev. Neurosci. 5: 863-873.
40. Zhang, M., Wong, I. G., Gin, J. B., and Ansari, N. H. 2009. Assessment of methylsulfonyl-methane as a permeability enhancer for regional EDTAchelationtherapy Drug Deliv. 16:243-248.
41. Zheng, H., Weiner, L. M., Bar-Am, O., Epsztejn, S., Cabantchik, Z. I., Warshawsky, A., Youdim, M. B., and Fridkin, M. 2005. Design, synthesis, and evaluation of novel bifunctional iron-chelatorsas potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg. Med. Chem. 13:773-783.